- Sangamo Therapeutics continues to develop their impressive pipeline of both wholly-owned and partnered programs. Sangamo has the potential to receive up to $7B in milestone payments from these pipeline programs.
- The company's gene therapy for hemophilia A is moving closer to a BLA. The company expects to report updated safety and efficacy results that should reveal SB-525's durability.
- The small-cap biotech sell-off has crushed SGMO's share price to fresh 52-week lows. I am looking to reload my position ahead of several potent catalysts.
For further details see:
Sangamo Therapeutics: Finding An Opportunity To Reload